Table 1 Patient demographic and baseline clinical characteristics
Moderately Emetogenic Chemotherapy | Highly Emetogenic Chemotherapy | |||||
|---|---|---|---|---|---|---|
APF530 250 mg n = 149 | APF530 500 mg n = 140 | Palonosetron 0.25 mg n = 134 | APF530 250 mg n = 60 | APF530 500 mg n = 67 | Palonosetron 0.25 mg n = 58 | |
Age, mean (SD), y | 53.3 (12.05) | 54.3 (11.96) | 55.0 (11.24) | 50.3 (10.83) | 49.8 (9.59) | 52.6 (12.66) |
Female, n (%) | 149 (100) | 137 (97.9) | 132 (98.5) | 60 (100) | 67 (100) | 58 (100) |
ECOG PS 0–1, n (%) | 145 (97.3) | 140 (100) | 131 (97.8) | 59 (98.3) | 65 (97.0) | 56 (96.6) |
Race/ethnicity, n (%) | ||||||
White or Caucasian | 80 (53.7) | 83 (59.3) | 94 (70.1) | 17 (28.3) | 35 (52.2) | 32 (55.2) |
Black or African American | 11 (7.4) | 15 (10.7) | 12 (9.0) | 8 (13.3) | 3 (4.5) | 1 (1.7) |
Hispanic or Latino | 12 (8.1) | 9 (6.4) | 6 (4.5) | 6 (10.0) | 6 (9.0) | 5 (8.6) |
Asian | 42 (28.2) | 30 (21.4) | 22 (16.4) | 25 (41.7) | 22 (32.8) | 20 (34.5) |
Other | 4 (2.7) | 3 (2.1) | 0 | 4 (6.7) | 1(1.5) | 0 |
Hesketh class, n (%) | ||||||
1–2 | 0 | 0 | 1 (0.7) | 0 | 0 | 0 |
3 | 3 (2.0) | 6 (4.3) | 6 (4.5) | 0 | 0 | 0 |
4 | 145 (97.3) | 131 (93.6) | 127 (94.8) | 2 (3.3) | 3 (4.5) | 1 (1.7) |
5 | 1 (0.7) | 3 (2.1) | 0 | 58 (96.7) | 64 (95.5) | 57 (98.3) |